|
1
|
Jemal A, Siegel R, Ward E, Hao Y, Xu J and
Thun MJ: Cancer statistics, 2009. CA Cancer J Clin. 59:225–249.
2009.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Pallis AG, Gridelli C, Wedding U,
Faivre-Finn C, Veronesi G, Jaklitsch M, Luciani A and O'Brien M:
Management of elderly patients with NSCLC; updated expert's opinion
paper: EORTC elderly task force, lung cancer group and
international society for geriatric oncology. Ann Oncol.
25:1270–1283. 2014.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Shirasaka T, Shimamato Y, Ohshimo H,
Yamaguchi M, Kato T, Yonekura K and Fukushima M: Development of a
novel form of an oral 5-fluorouracil derivative (S-1) directed to
the potentiation of the tumor selective cytotoxicity of
5-fluorouracil by two biochemical modulators. Anticancer Drugs.
7:548–557. 1996.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Nishiyama O, Taniguchi H, Kondoh Y, Takada
K, Baba K, Saito H, Sugino Y, Yamamoto M, Ogasawara T, Kondo M, et
al: Phase II study of S-1 monotherapy as a first-line treatment for
elderly patients with advanced nonsmall-cell lung cancer: The
Central Japan lung study group trial 0404. Anticancer Drugs.
22:811–816. 2011.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Shiroyama T, Kijima T, Komuta K, Yamamoto
S, Minami S, Ogata Y, Okafuji K, Imamura F, Hirashima T, Tachibana
I, et al: Phase II tailored S-1 regimen study of first-line
chemotherapy in elderly patients with advanced and recurrent
non-small cell lung cancer. Cancer Chemother Pharmacol. 70:783–789.
2012.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Goto H, Okano Y, Machida H, Hatakeyama N,
Ogushi F, Haku T, Kanematsu T, Urata T, Kakiuchi S, Hanibuchi M, et
al: Phase II study of tailored S-1 monotherapy with a 1-week
interval after a 2-week dosing period in elderly patients with
advanced non-small cell lung cancer. Respir Investig. 56:80–86.
2018.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Yamamoto H, Soh J, Okumura N, Suzuki H,
Nakata M, Fujiwara T, Gemba K, Sano I, Fujinaga T, Kataoka M, et
al: Randomized phase II study of daily versus alternate-day
administrations of S-1 for the elderly patients with completely
resected pathological stage IA (tumor diameter >2 cm)-IIIA of
non-small cell lung cancer: Setouchi lung cancer group study 1201.
PLoS One. 18(e0285273)2023.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Rustum YM, Harstrick A, Cao S, Vanhoefer
U, Yin MB, Wilke H and Seeber S: Thymidylate synthase inhibitors in
cancer therapy: Direct and indirect inhibitors. J Clin Oncol.
15:389–400. 1997.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Peters GJ, Laurensse E, Leyva A, Lankelma
J and Pinedo HM: Sensitivity of human, murine, and rat cells to
5-fluorouracil and 5'-deoxy-5-fluorouridine in relation to
drug-metabolizing enzymes. Cancer Res. 46:20–28. 1986.PubMed/NCBI
|
|
10
|
Peters GJ, van Groeningen CJ, Laurensse EJ
and Pinedo HM: A comparison of 5-fluorouracil metabolism in human
colorectal cancer and colon mucosa. Cancer. 68:1903–1909.
1991.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Beck A, Etienne MC, Chéradame S, Fischel
JL, Formento P, Renée N and Milano G: A role for dihydropyrimidine
dehydrogenase and thymidylate synthase in tumour sensitivity to
fluorouracil. Eur J Cancer. 30A:1517–1522. 1994.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Suehisa H, Toyooka S, Hotta K, Uchida A,
Soh J, Fujiwara Y, Matsuo K, Ouchida M, Takata M, Kiura K and Date
H: Epidermal growth factor receptor mutation status and adjuvant
chemotherapy with uracil-tegafur for adenocarcinoma of the lung. J
Clin Oncol. 25:3952–3957. 2007.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Tsutani Y, Ito M, Shimada Y, Ito H, Ikeda
N, Nakayama H and Okada M: The impact of epidermal growth factor
receptor mutation status on adjuvant chemotherapy for patients with
high-risk stage I lung adenocarcinoma. J Thorac Cardiovasc Surg.
164:1306–1315.e4. 2022.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Wei J, Zou Z, Qian X, Ding Y, Xie L,
Sanchez JJ, Zhao Y, Feng J, Ling Y, Liu Y, et al: ERCC1 mRNA levels
and survival of advanced gastric cancer patients treated with a
modified FOLFOX regimen. Br J Cancer. 98:1398–1402. 2008.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Shigematsu H, Lin L, Takahashi T, Nomura
M, Suzuki M, Wistuba II, Fong KM, Lee H, Toyooka S, Shimizu N, et
al: Clinical and biological features associated with epidermal
growth factor receptor gene mutations in lung cancers. J Natl
Cancer Inst. 97:339–346. 2005.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Tokumo M, Toyooka S, Kiura K, Shigematsu
H, Tomii K, Aoe M, Ichimura K, Tsuda T, Yano M, Tsukuda K, et al:
The relationship between epidermal growth factor receptor mutations
and clinicopathologic features in non-small cell lung cancers. Clin
Cancer Res. 11:1167–1173. 2005.PubMed/NCBI
|
|
17
|
Soh J, Toyooka S, Matsuo K, Yamamoto H,
Wistuba II, Lam S, Fong KM, Gazdar AF and Miyoshi S: Ethnicity
affects EGFR and KRAS gene alterations of lung
adenocarcinoma. Oncol Lett. 10:1775–1782. 2015.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Viñuela A, Snoek LB, Riksen JA and
Kammenga JE: Genome-wide gene expression regulation as a function
of genotype and age in C. elegans. Genome Res. 20:929–937.
2010.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Li Z, Wright FA and Royland J:
Age-dependent variability in gene expression in male Fischer 344
rat retina. Toxicol Sci. 107:281–292. 2009.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Yang J, Huang T, Petralia F, Long Q, Zhang
B, Argmann C, Zhao Y, Mobbs CV, Schadt EE, Zhu J, et al:
Synchronized age-related gene expression changes across multiple
tissues in human and the link to complex diseases. Sci Rep.
5(15145)2015.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Peters MJ, Joehanes R, Pilling LC,
Schurmann C, Conneely KN, Powell J, Reinmaa E, Sutphin GL,
Zhernakova A, Schramm K, et al: The transcriptional landscape of
age in human peripheral blood. Nat Commun. 6(8570)2015.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Jang H, Mason JB and Choi SW: Genetic and
epigenetic interactions between folate and aging in carcinogenesis.
J Nutr. 135 (Suppl):2967S–2971S. 2005.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Soh J, Okumura N, Lockwood WW, Yamamoto H,
Shigematsu H, Zhang W, Chari R, Shames DS, Tang X, MacAulay C, et
al: Oncogene mutations, copy number gains and mutant allele
specific imbalance (MASI) frequently occur together in tumor cells.
PLoS One. 4(e7464)2009.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Liang Z, Zhang J, Zeng X, Gao J, Wu S and
Liu T: Relationship between EGFR expression, copy number and
mutation in lung adenocarcinomas. BMC Cancer.
10(376)2010.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Pinter F, Papay J, Almasi A, Sapi Z, Szabo
E, Kanya M, Tamasi A, Jori B, Varkondi E, Moldvay J, et al:
Epidermal growth factor receptor (EGFR) high gene copy number and
activating mutations in lung adenocarcinomas are not consistently
accompanied by positivity for EGFR protein by standard
immunohistochemistry. J Mol Diagn. 10:160–168. 2008.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Mochinaga K, Tsuchiya T, Nagasaki T, Arai
J, Tominaga T, Yamasaki N, Matsumoto K, Miyazaki T, Nanashima A,
Hayashi T, et al: High expression of dihydropyrimidine
dehydrogenase in lung adenocarcinoma is associated with mutations
in epidermal growth factor receptor: Implications for the treatment
of non-small-cell lung cancer using 5-fluorouracil. Clin Lung
Cancer. 15:136–144.e4. 2014.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Tominaga T, Tsuchiya T, Mochinaga K, Arai
J, Yamasaki N, Matsumoto K, Miyazaki T, Nagasaki T, Nanashima A,
Tsukamoto K and Nagayasu T: Epidermal growth factor signals
regulate dihydropyrimidine dehydrogenase expression in EGFR-mutated
non-small-cell lung cancer. BMC Cancer. 16(354)2016.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Zhang L, Pradhan B, Guo L, Meng F and
Zhong D: EGFR exon 19-deletion aberrantly regulate ERCC1 expression
that may partly impaired DNA damage repair ability in non-small
cell lung cancer. Thorac Cancer. 11:277–285. 2020.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Lin CS, Liu TC, Lai JC, Yang SF and Tsao
TC: Evaluating the prognostic value of ERCC1 and thymidylate
synthase expression and the epidermal growth factor receptor
mutation status in adenocarcinoma non-small-cell lung cancer. Int J
Med Sci. 14:1410–1417. 2017.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Gandara DR, Grimminger P, Mack PC, Lara PN
Jr, Li T, Danenberg PV and Danenberg KD: Association of epidermal
growth factor receptor activating mutations with low ERCC1 gene
expression in non-small cell lung cancer. J Thorac Oncol.
5:1933–1938. 2010.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Ren S, Chen X, Kuang P, Zheng L, Su C, Li
J, Li B, Wang Y, Liu L, Hu Q, et al: Association of EGFR mutation
or ALK rearrangement with expression of DNA repair and synthesis
genes in never-smoker women with pulmonary adenocarcinoma. Cancer.
118:5588–5594. 2012.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Nakamura H, Kawasaki N, Taguchi M and
Kabasawa K: Survival impact of epidermal growth factor receptor
overexpression in patients with non-small cell lung cancer: A
meta-analysis. Thorax. 61:140–145. 2006.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Takeda M, Okamoto I, Hirabayashi N, Kitano
M and Nakagawa K: Thymidylate synthase and dihydropyrimidine
dehydrogenase expression levels are associated with response to S-1
plus carboplatin in advanced non-small cell lung cancer. Lung
Cancer. 73:103–109. 2011.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Honma Y, Togo S, Shimizu K, Tulafu M,
Hayashi T, Uekusa T, Tominaga S, Kido K, Fujimoto Y, Nanba Y, et
al: Expression of thymidylate synthase predicts clinical outcomes
of S-1-based chemotherapy in squamous cell lung cancer. Oncol Lett.
14:3319–3326. 2017.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Liu Q, Yu Z, Xiang Y, Wu N, Wu L, Xu B,
Wang L, Yang P, Li Y and Bai L: Prognostic and predictive
significance of thymidylate synthase protein expression in
non-small cell lung cancer: A systematic review and meta-analysis.
Cancer Biomark. 15:65–78. 2015.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Huang CL, Yokomise H, Kobayashi S,
Fukushima M, Hitomi S and Wada H: Intratumoral expression of
thymidylate synthase and dihydropyrimidine dehydrogenase in
non-small cell lung cancer patients treated with 5-FU-based
chemotherapy. Int J Oncol. 17:47–54. 2000.PubMed/NCBI
|
|
37
|
Nakano J, Huang C, Liu D, Masuya D,
Nakashima T, Yokomise H, Ueno M, Wada H and Fukushima M:
Evaluations of biomarkers associated with 5-FU sensitivity for
non-small-cell lung cancer patients postoperatively treated with
UFT. Br J Cancer. 95:607–615. 2006.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Lenz HJ, Leichman CG, Danenberg KD,
Danenberg PV, Groshen S, Cohen H, Laine L, Crookes P, Silberman H,
Baranda J, et al: Thymidylate synthase mRNA level in adenocarcinoma
of the stomach: A predictor for primary tumor response and overall
survival. J Clin Oncol. 14:176–182. 1996.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Okabe T, Okamoto I, Tsukioka S, Uchida J,
Hatashita E, Yamada Y, Yoshida T, Nishio K, Fukuoka M, Jänne PA and
Nakagawa K: Addition of S-1 to the epidermal growth factor receptor
inhibitor gefitinib overcomes gefitinib resistance in non-small
cell lung cancer cell lines with MET amplification. Clin Cancer
Res. 15:907–913. 2009.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Okabe T, Okamoto I, Tsukioka S, Uchida J,
Iwasa T, Yoshida T, Hatashita E, Yamada Y, Satoh T, Tamura K, et
al: Synergistic antitumor effect of S-1 and the epidermal growth
factor receptor inhibitor gefitinib in non-small cell lung cancer
cell lines: Role of gefitinib-induced down-regulation of
thymidylate synthase. Mol Cancer Ther. 7:599–606. 2008.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Takezawa K, Okamoto I, Tanizaki J, Kuwata
K, Yamaguchi H, Fukuoka M, Nishio K and Nakagawa K: Enhanced
anticancer effect of the combination of BIBW2992 and thymidylate
synthase-targeted agents in non-small cell lung cancer with the
T790M mutation of epidermal growth factor receptor. Mol Cancer
Ther. 9:1647–1656. 2010.PubMed/NCBI View Article : Google Scholar
|
|
42
|
Sheng M, Wang F, Zhao Y, Li S, Wang X,
Shou T, Luo Y and Tang W: Comparison of clinical outcomes of
patients with non-small-cell lung cancer harbouring epidermal
growth factor receptor exon 19 or exon 21 mutations after tyrosine
kinase inhibitors treatment: A meta-analysis. Eur J Clin Pharmacol.
72:1–11. 2016.PubMed/NCBI View Article : Google Scholar
|
|
43
|
Eck MJ and Yun CH: Structural and
mechanistic underpinnings of the differential drug sensitivity of
EGFR mutations in non-small cell lung cancer. Biochim Biophys Acta.
1804:559–566. 2010.PubMed/NCBI View Article : Google Scholar
|
|
44
|
Carey KD, Garton AJ, Romero MS, Kahler J,
Thomson S, Ross S, Park F, Haley JD, Gibson N and Sliwkowski MX:
Kinetic analysis of epidermal growth factor receptor somatic mutant
proteins shows increased sensitivity to the epidermal growth factor
receptor tyrosine kinase inhibitor, erlotinib. Cancer Res.
66:8163–8171. 2006.PubMed/NCBI View Article : Google Scholar
|
|
45
|
Okabe T, Okamoto I, Tamura K, Terashima M,
Yoshida T, Satoh T, Takada M, Fukuoka M and Nakagawa K:
Differential constitutive activation of the epidermal growth factor
receptor in non-small cell lung cancer cells bearing EGFR gene
mutation and amplification. Cancer Res. 67:2046–2053.
2007.PubMed/NCBI View Article : Google Scholar
|
|
46
|
Cho J, Chen L, Sangji N, Okabe T, Yonesaka
K, Francis JM, Flavin RJ, Johnson W, Kwon J, Yu S, et al: Cetuximab
response of lung cancer-derived EGF receptor mutants is associated
with asymmetric dimerization. Cancer Res. 73:6770–6779.
2013.PubMed/NCBI View Article : Google Scholar
|
|
47
|
Imai H, Minemura H, Kishikawa T, Yamada Y,
Suzuki K, Umeda Y, Wasamoto S, Kasahara N, Ishihara S, Yamaguchi O,
et al: Efficacy and safety of S-1 monotherapy in previously treated
elderly patients (aged ≥75 years) with non-small cell lung cancer:
A retrospective analysis. Thorac Cancer. 11:2867–2876.
2020.PubMed/NCBI View Article : Google Scholar
|
|
48
|
Tsuchiya T, Arai J, Matsumoto K, Miyazaki
T, Honda S, Tagawa T, Nakamura A, Taniguchi H, Sano I, Akamine S,
et al: Prognostic impact of the ABCC11/MRP8 polymorphism in
adjuvant oral chemotherapy with S-1 for non-small cell lung cancer.
Chemotherapy. 61:77–86. 2016.PubMed/NCBI View Article : Google Scholar
|
|
49
|
Uemura T, Oguri T, Maeno K, Sone K,
Takeuchi A, Fukuda S, Kunii E, Takakuwa O, Kanemitsu Y, Ohkubo H,
et al: ABCC11 gene polymorphism as a potential predictive biomarker
for an oral 5-fluorouracil derivative drug S-1 treatment in
non-small cell lung cancer. Cancer Chemother Pharmacol.
84:1229–1239. 2019.PubMed/NCBI View Article : Google Scholar
|
